Th1

GSK-J4 (GSK J4 HCl) is a cell permeable prodrug of GSK-J1, a dual inhibitor of the H3K27me3/me2 demethylases JMJD3/KDM6B and UTX/KDM6A (IC50=8.6/6.6 μM). GSK-J4 induces endoplasmic reticulum stress-related apoptosis.

SM360320 (CL-087) is an effective and selective agonist of TLR7. SM360320 inhibits HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity. SM360320 can be used for research on acting as an immunological adjuv

GSK-J4 Hydrochloride (GSK J4 HCl) is a cell permeable, potent and selective histone demethylase(JMJD3 )inhibitor. is an ethyl ester derivative of the GSK-J1 with an IC50 value greater than 50 μM in vitro.

Resiniferatoxin ((+)-Resiniferatoxin) is a highly potent synthetic TRPV1 agonist that inhibits the production of Th1 cytokines and has anti-inflammatory activity, reducing serum levels of IL-12, INF-γ, IL-1β, TNF-α, NO, and PGE.

MTH1-IN-2 is an inhibitor of MutT homolog 1 (MTH1), with anti-tumor activity.

TH1834 dihydrochloride, a specific Tip60 histone acetyltransferase inhibitor, induces apoptosis and enhances DNA damage in breast cancer (Type: BrCa).

MTH1 ligand 1 functions as a target protein ligand for MTH1, and is utilized in the synthesis of PROTACaTAG 2139.

MTH1 degrader-1 is an inhibitor of MTH1 aTAG and serves as a ligand for target proteins in PROTAC applications. It is used in the synthesis of PROTAC aTAG 4531.

TH152 is a general reversible ligand for LC3/GABARAP with a dissociation constant (KD) of 2 µM. LC3/GABARAP is a protein associated with autophagy.

MTH1 activator-1 is an MTH1 activator that enhances endogenous MTH1 activity and significantly reduces 8-oxo-dG levels in cellular DNA. It is useful for investigating the upregulation of oxidative damage repair in nucleotide pools and examining biological effects, as well as for studies aiming to delay or prevent tumorigenesis.

TH10184-octanedioic acid is a conjugate of the NUDT5 ligand and linker. It is utilized in the synthesis of DDD2, which is a PROTAC targeting degrader for NUDT5.

TH10184 is an inhibitor of NUDT5. It can be conjugated with VH032 and a linker to form a PROTAC-targeted degrader of NUDT5, known as DDD2.

TH16 is an antimicrobial agent with a minimum inhibitory concentration (MIC) of 2 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). It disrupts the integrity of the bacterial cytoplasmic membrane, leading to an increase in intracellular reactive oxygen species (ROS) levels, ultimately causing bacterial death. TH16 holds potential for research in bacterial infection.

TH1338 is an orally active derivative of camptothecin with potential anti-cancer activity. TH1338 exhibits significant blood-brain barrier penetration and cytotoxicity, useful for cancer research.

ITH15004 is a non-nucleotide antagonist of the purinergic P2X7receptor (IC50= 9 μM in HEK293 cells expressing the human receptor).1It inhibits ATP-induced currents inX. laevisoocytes expressing the human P2X7receptor when used at a concentration of 100 μM. ITH15004 (1 μM) decreases IL-1β release from LPS-primed, ATP-stimulated isolated mouse peritoneal macrophages. It has high permeability in a parallel artificial membrane permeability assay (PAMPA). 1.Calzaferri, F., Narros-Fernández, P., de Pascual, R., et al.Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammationJ. Med. Chem.64(4)2272-2290(2021)

TH1217, a potent and selective inhibitor of dCTPase pyrophosphatase 1 (dCTPase), demonstrates an IC50 value of 47 nM. It amplifies the cytotoxic impact of cytidine analogues on leukemia cells and exhibits potential against COVID-19 by modulating SARS-CoV-2 interactors.

TH1834 is a specific inhibitor of Tip60/KAT5 histone acetyltransferase. TH1834 induces apoptosis and DNA damage in breast cancer cells (MCF7) without affecting the activity of the related histone acetyltransferase MOF.

TH1085 is an enhancer of OGG1. TH1085 stimulates DNA repair and protects cells from the environmental hazard paraquat (PQ).

TH1760 (MKB) is an inhibitor of NUDIX-type 15 (NUDT15, IC50= 25 nM). TH1760 can sensitize cells to 6-thioguanine by increasing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 can enhance the anti-leukemia effect of thiopurine.

ITH12711, a PP2A ligand, can traverse the blood-brain barrier (BBB) and exerts neuroprotection by restoring PP2A-phosphatase activity [1].

TH1020 is a novel Inhibitor of Toll-Like Receptor 5 (TLR5)/Flagellin Complex with promising activity (IC50 =0.85±0.12 μm) and specificity.

BTH1704 is a human monoclonal antibody targeting MUC1. It facilitates the killing of iC3b-opsonized tumor cells by leukocytes triggered by PGG. BTH1704 is applicable in studies on pancreatic cancer and breast cancer.

CMP-5 is a PRMT5 inhibitor with antiviral activity, inhibits PRMT5 methyltransferase activity, and can be used in the study of SARS virus infection.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].